Volume 122, Issue 4, Pages 923-930 (April 2002) Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: A retrospective multicenter study  Richard Moreau, Francois Durand, Thierry Poynard, Christian Duhamel, Jean–Paul Cervoni, Philippe Ichaï, Armand Abergel, Chantal Halimi, Mathieu Pauwels, Jean–Pierre Bronowicki, Emile Giostra, Cathy Fleurot, Danielle Gurnot, Olivier Nouel, Philippe Renard, Michel Rivoal, Pierre Blanc, Dimitri Coumaros, Sylvie Ducloux, Stephane Levy, Alexandre Pariente, Jean–Marc Perarnau, Jean Roche, Myriam Scribe–Outtas, Dominique Valla, Brigitte Bernard, Didier Samuel, JoëL Butel, Antoine Hadengue, Andrzej Platek, Didier Lebrec, Jean– Francois Cadranel  Gastroenterology  Volume 122, Issue 4, Pages 923-930 (April 2002) DOI: 10.1053/gast.2002.32364 Copyright © 2002 American Gastroenterological Association Terms and Conditions

Fig. 1 Probability of survival in 99 patients with type 1 HRS treated with terlipressin. Vertical bars correspond to patients who underwent liver transplantation. Gastroenterology 2002 122, 923-930DOI: (10.1053/gast.2002.32364) Copyright © 2002 American Gastroenterological Association Terms and Conditions

Fig. 2 Probability of survival in patients with type 1 HRS who had improved renal function during terlipressin therapy and in those who did not. P value was determined by the log-rank test. Gastroenterology 2002 122, 923-930DOI: (10.1053/gast.2002.32364) Copyright © 2002 American Gastroenterological Association Terms and Conditions

Fig. 3 Probability of survival in patients with type 1 HRS treated with terlipressin according to the value of the Child–Pugh score (≤11 vs. >11) at inclusion. P value was determined by the log-rank test. Gastroenterology 2002 122, 923-930DOI: (10.1053/gast.2002.32364) Copyright © 2002 American Gastroenterological Association Terms and Conditions

Fig. 4 Probability of survival in patients with type 1 HRS treated with terlipressin according to the type of plasma expander (human albumin vs. other plasma expanders) administered to compensate for paracentesis during the pre-HRS period (i.e., within the month before inclusion). P value was determined by the log-rank test. Gastroenterology 2002 122, 923-930DOI: (10.1053/gast.2002.32364) Copyright © 2002 American Gastroenterological Association Terms and Conditions

Fig. 5 Probability of survival in patients with type 1 HRS treated with terlipressin according to the presence or absence of severe infection (SBP, septicemia, or pneumonia) during the pre-HRS period (i.e., within the month before inclusion). P value was determined by the log-rank test. Gastroenterology 2002 122, 923-930DOI: (10.1053/gast.2002.32364) Copyright © 2002 American Gastroenterological Association Terms and Conditions